166 related articles for article (PubMed ID: 37057033)
21. Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Vienne A; Collet L; Chevalier T; Borel C; Tardy M; Huguet F; Richard S; Salas S; Saada-Bouzid E; Fayette J; Daste A
BMC Cancer; 2023 Jul; 23(1):663. PubMed ID: 37452287
[TBL] [Abstract][Full Text] [Related]
22. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
Huang S; Xiong C; Tan K
Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
[TBL] [Abstract][Full Text] [Related]
24. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
25. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
Green SE; McCusker MG; Mehra R
Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
[No Abstract] [Full Text] [Related]
26. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
27. Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
Lien MY; Wang TH; Hsieh CY; Tsai MH; Hua CH; Cheng FM; Chung WH; Tang CH; Chia-Hsun Hsieh J
Oral Oncol; 2021 Aug; 119():105380. PubMed ID: 34146822
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
29. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
[TBL] [Abstract][Full Text] [Related]
30. Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients.
Foy JP; Karabajakian A; Ortiz-Cuaran S; Boussageon M; Michon L; Bouaoud J; Fekiri D; Robert M; Baffert KA; Hervé G; Quilhot P; Attignon V; Girod A; Chaine A; Benassarou M; Zrounba P; Caux C; Ghiringhelli F; Lantuejoul S; Crozes C; Brochériou I; Pérol M; Fayette J; Bertolus C; Saintigny P
Eur J Cancer; 2022 Oct; 174():287-298. PubMed ID: 36038492
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
Dang S; Zhang S; Zhao J; Li X; Li W
Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with immune checkpoint inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: A meta-analysis.
Chen L; Mo DC; Hu M; He W; Yang QW; Tang J
Int Immunopharmacol; 2023 Jun; 119():110270. PubMed ID: 37150013
[TBL] [Abstract][Full Text] [Related]
33. The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer.
Haas M; Lein A; Fuereder T; Brkic FF; Schnoell J; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839241
[TBL] [Abstract][Full Text] [Related]
34. Role of PD-1/PD-L1 inhibitors in the treatment of recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yin G; Guo W; Duan H; Huang Z
Clin Otolaryngol; 2021 Sep; 46(5):1013-1020. PubMed ID: 33765363
[TBL] [Abstract][Full Text] [Related]
35. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.
Clarke E; Eriksen JG; Barrett S
Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
[TBL] [Abstract][Full Text] [Related]
37. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
[TBL] [Abstract][Full Text] [Related]
38. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma.
Hoffmann F; Franzen A; de Vos L; Wuest L; Kulcsár Z; Fietz S; Maas AP; Hollick S; Diop MY; Gabrielpillai J; Vogt T; Kuster P; Zarbl R; Dietrich J; Kristiansen G; Brossart P; Landsberg J; Strieth S; Dietrich D
Clin Epigenetics; 2023 Jul; 15(1):112. PubMed ID: 37415208
[TBL] [Abstract][Full Text] [Related]
39. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
